A treatment to protect intestinal stem cells from radiation damage
Official title: Anti-ceramide Ab Preserves Intestinal Stem Cells and Prevents GI-ARS and GI-DEARE
Funded at Sloan-Kettering Inst Can Research · NIH-11017462 · Data updated 2026-11-12
This study is looking at a new way to help protect the cells in your gut from damage caused by radiation, which can happen during certain medical treatments or emergencies, by using a special antibody that may help them recover better.
Quick facts
| Grant type | U01 cooperative agreement |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Sloan-Kettering Inst Can Research NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project start | December 2, 2024 |
| Project end | November 30, 2029 |
| Funding year | 2025 |
| Award (this year) | $597,518 |
| NIH project number | 1U01AI187049-01 |
| Project ID | NIH-11017462 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research would include individuals who are at risk of acute radiation exposure, such as patients undergoing radiation therapy or those exposed to radiation in emergency situations.
✕Less likely to help
Patients who have not been exposed to radiation or those with pre-existing gastrointestinal conditions unrelated to radiation may not benefit from this research.
What this research studies
This research focuses on developing an anti-ceramide antibody to protect intestinal stem cells from damage caused by acute radiation syndrome (GI-ARS). The approach involves understanding how radiation leads to the depletion of these critical cells, which are essential for maintaining the integrity of the gastrointestinal tract. By targeting the mechanisms that lead to cell death, the researchers aim to improve recovery and reduce the severity of GI-ARS. The study will involve preclinical models to test the effectiveness of the anti-ceramide antibody in preventing intestinal damage after radiation exposure.
Why it matters
Potential benefit: If successful, this research could significantly reduce morbidity and mortality associated with gastrointestinal damage from radiation exposure.
How similar studies have gone: While the approach of using anti-ceramide antibodies is novel, similar strategies targeting cell protection in radiation exposure have shown promise in preliminary studies.
Where this research is happening
-
Sloan-Kettering Inst Can Research
New York, United States Active
Researchers
- Principal investigator: Kolesnick, Richard N — Sloan-Kettering Inst Can Research
- Study coordinator: Kolesnick, Richard N
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.